氯胺酮
5-羟色胺能
抗抑郁药
抑郁症动物模型
药理学
NBQX公司
雷波西汀
AMPA受体
西酞普兰
医学
血清素
NMDA受体
神经科学
内科学
内分泌学
再摄取抑制剂
心理学
受体
海马体
作者
Yongchang Yin,Jiao‐Zhao Yan,Qianqian Wei,Si‐Rui Sun,Yu‐Qiang Ding,Liming Zhang,Yunfeng Li
摘要
Abstract Background and Purpose The emerging antidepressant effects of ketamine have inspired tremendous interest in its underlying neurobiological mechanisms, although the involvement of 5‐HT in the antidepressant effects of ketamine remains unclear. Experimental approach The chronic restraint stress procedure was performed to induce depression‐like behaviours in mice. OFT, FST, TST, and NSFT tests were used to evaluate the antidepressant‐like effects of ketamine. Tph2 knockout or depletion of 5‐HT by PCPA and 5,7‐DHT were used to manipulate the brain 5‐HT system. ELISA and fibre photometry recordings were used to measure extracellular 5‐HT levels in the brain. Key Results 60 min after injection, ketamine (10 mg·kg −1 , i.p.) produced rapid antidepressant‐like effects and increased brain 5‐HT levels. After 24 h, ketamine significantly reduced immobility time in TST and FST tests and increased brain 5‐HT levels, as measured by ELISA and fibre photometry recordings. The sustained (24 h) but not rapid (60 min) antidepressant‐like effects of ketamine were abrogated by PCPA and 5,7‐DHT, or by Tph2 knockout. Importantly, NBQX (10 mg·kg −1 , i.p.), an AMPA receptor antagonist, significantly inhibited the effect of ketamine on brain 5‐HT levels and abolished the sustained antidepressant‐like effects of ketamine in naïve or CRS‐treated mice. Conclusion and Implications This study confirms the requirement of serotonergic neurotransmission for the sustained antidepressant‐like effects of ketamine, which appears to involve AMPA receptors, and provides avenues to search for antidepressant pharmacological targets.
科研通智能强力驱动
Strongly Powered by AbleSci AI